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Abstract
Nanotechnology in diabetes research has facilitated the development of novel glucose 
measurement and insulin delivery modalities which hold the potential to dramatically improve 
quality of life for diabetics. Recent progress in the field of diabetes research at its interface with 
nanotechnology is our focus. In particular, we examine glucose sensors with nanoscale 
components including metal nanoparticles and carbon nanostructures. The addition of nanoscale 
components commonly increases glucose sensor sensitivity, temporal response, and can lead to 
sensors which facilitate continuous in vivo glucose monitoring. Additionally, we survey nanoscale 
approaches to “closed-loop” insulin delivery strategies which automatically release insulin in 
response to fluctuating blood glucose levels. “Closing the loop” between blood glucose level 
(BGL) measurements and insulin administration by removing the requirement of patient action 
holds the potential to dramatically improve the health and quality of life of diabetics. Advantages 
and limitations of current strategies, as well as future opportunities and challenges are also 
discussed.
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Introduction
Diabetes is a metabolic disease characterized by chronically elevated blood glucose levels 
(BGLs) and an inability to maintain BGL homeostasis1, 2. Individuals with type 1 diabetes 
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cannot produce insulin as a result of autoimmune destruction of the insulin producing cells 
within the pancreas, known as beta cells3. Type 2 diabetes is characterized by insulin 
resistance, or a deficiency in cellular response to insulin in the bloodstream2. In both cases, 
the loss of homeostasis-regulation mechanisms can lead to chronically high and low blood 
glucose levels known as hyperglycaemia or hypoglycemiea3. Chronic hyperglycaemia can 
lead to a variety of symptoms including cardiovascular and neurological complications4, 
while hypoglycaemia can lead to lack of energy, unconsciousness, and death5. Diabetes has 
grown to become one of largest public health challenges globally, affecting 25.8 million in 
the United States and 382 million worldwide; and this number is expected to grow to 592 
million by 20355, 6. Furthermore, diabetes is expected to become the seventh largest cause 
of death worldwide by 20304. The current standard of care for type 1 and advanced type 2 
diabetics involves daily subcutaneous insulin injections, and frequent finger pricks to draw 
blood for the measurement of BGLs5. Daily insulin injections are painful and lead to patient 
noncompliance, and can lead to dangerous insulin overdoses5. Additionally, periodic 
measurement of blood glucose may not detect large fluctuations in BGLs which occur 
between points of measurement. Therefore, systems which improve blood glucose 
monitoring, or “close the loop” between glucose measurement and insulin delivery, are 
highly desirable.
The application of nanotechnology to medicine holds many possible advantages, such as 
access to small and clinically relevant areas of cells and analysis of small volumes of 
analytes. Additionally, the emergence of quantum effects leads to interesting and useful 
physical properties; for example, nanoscale carbon is stronger than steel, highly malleable, 
fluorescent, and exhibits excellent electrical conductivity7. Figure 1 displays typical research 
themes using nanotechnology for diabetes treatment. For example, the improved glucose 
sensor technology has an immediate and significant impact on the health of diabetics, as 
improved sensing will lead to more accurate insulin dosing and diabetes management. 
Indeed, advances in nanomedicine have already facilitated novel sensors which are capable 
of more frequent and convenient blood glucose measurements6, 8–12. Nanomedicine has also 
enabled more robust insulin delivery systems that can detect fluctuations in BGLs and 
automatically modulate the rate of insulin release to maintain normoglycemiea6, 13. Such 
systems represent a tremendous advancement over contemporary standards of care. The 
clinical application of these technologies will allow diabetics to manage their disease more 
effectively and improve their health and quality of life.
Nanotechnology Enabled Glucose Sensing
Accurate and frequent glucose measurements are the basis of contemporary diabetes 
management. However, it is commonly acknowledged that contemporary clinical glucose 
measurement systems are a nuisance to the patient as a result of frequent and painful needle 
sticks, and the current standard of intermittent testing can miss dangerous fluctuations in 
blood glucose concentration7, 14. Therefore, one of the most significant challenges in 
diabetes research is the development of glucose sensors which achieve accurate glucose 
measurements painlessly and frequently, with the goal of continuous glucose measurement. 
A wide variety of glucose sensing modalities have been reported in the last two decades, and 
commonly employ Concanavalin A (Con A), phenylboronic acid (PBA), or most commonly, 
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Glucose Oxidase (GOx) as a sensor for detecting glucose in solution. Common interfering 
species in blood and other bodily fluids include Uric and Acetic acids, as well as other 
carbohydrates such as Fructose, Lactose, and Sucrose6, 11, 15. Specificity for measuring only 
Glucose in solution requires the use of glucose specific enzymes, or the use of chemical or 
physical barriers with other detection modalities16.
Broadly speaking, glucose measurement systems can be classified into two categories: 
electrical and optical. A common mechanism of glucose detection involves using hydrogen 
peroxide (H2O2) or a similar reduced species as a chemical intermediary which drives the 
reduction of another species. This in turn generates a measurable signal such as an increase 
or shift in flourescence6, 8, 11 or a change in current through an electrode of an amperometric 
sensor17–19. Advantages of hydrogen peroxide based detection schemes include relatively 
straightforward sensor operation and characterization via amperometric techniques, but 
disadvantages include the degenerative effects of hydrogen peroxide on the sensor, the 
relatively high electrical potential required to catalyse hydrogen peroxide, and the possibility 
of sensor interference20–22. As a result of the importance of quantifying the concentration of 
hydrogen peroxide in solution to other fields, many electrical-based H2O2 sensors have been 
developed or adapted for glucose measurement. A summary of nanotechnology enabled 
glucose sensing technologies is included in Table 1.
Electrochemical Glucose Measurement
The excellent conductivity and catalytic ability of nanoscale carbon structures has led to 
their use in a variety of glucose sensing modalities23–29. Additionally, electrically coupling 
glucose oxidase to nanoscale carbon structures modulates the electrical resistance of the 
structures24. The first to publish research on using a single carbon nanotube as a biosensor 
was Besteman, et al., who immobilized GOx on a semiconductor carbon nanotube via 1-
pyrenebutanoic acid succinimidyl ester, and found that the conductivity of the nanotube was 
correlated to the activity of the immobilized GOx’s response to the addition of glucose24. 
The addition of 0.1 mM glucose solution resulted in an approximate 10% increase in 
conductivity of the GOx-nanotube complex24. The system also exhibited a strong sensitivity 
to the pH of the surrounding solution24.
In most electrochemical methods, glucose concentration measurements are achieved by 
measuring an enzyme’s activity either directly by coupling it to an electrode or indirectly by 
measuring changes in concentration of the reactants or products. An advantage of coupling 
this technique with nanoscale components is that nanostructures such as carbon 
nanotubes24, 26, 27, 29 or gold nanoparticles17, 18 are excellent catalysts for reducing H2O2. 
Furthermore, the high surface area to volume ratio of nanostructures increases the reaction 
kinetics. Lin and co-workers applied the technique of hydrogen peroxide reduction to 
electrochemically detect glucose25. GOx was directly immobilized on carbon nanotubes by 
forming amide linkages between GOx’s amine residues and carboxylic acid groups on the 
carbon nanotubes via 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and N-hydroxysulfo-
succinimide25. At low operating voltages (−0.2 V), the H2O2 generated by GOx action could 
be efficiently catalysed by the nanotubes, resulting in current flow proportional to glucose 
concentration. A linear response from 0–30 mM was found, and a small limit of detection of 
DiSanto et al. Page 3













0.08 mM was reported. As opposed to large glucose sensing electrodes, the use of an array 
of many nanoscale electrodes increases the signal-to-noise ratio and the sensitivity of the 
sensor by increasing its functional surface area. Additionally, the use of small negative 
potentials can reduce the risk of interference from unwanted redox reactions which occur at 
higher potentials. It has also been demonstrated that combinations of nanoparticles work 
together synergistically to realize more efficient hydrogen peroxide catalyzation than can be 
realized with any single component. Shan et al. found that the combination of graphene, 
gold nanoparticles (AuNPs), and GOx within a nanocomposite material can cause an 
increase in the electrocatalyzation current of hydrogen peroxide and oxygen as a result of 
synergistic interactions between graphene and AuNPs17. They developed a glucose sensor 
based on this technology which could operate at low potential (−0.2 V) and was capable of 
accurately measuring human blood glucose concentrations from 2.5–7.5 mM17.
Yang and co-workers (Figure 2) compared similar micro- and nano-scale GOx electrodes, 
and found superior performance from the nanoscale sensors30. The micro scale electrode 
was based on a bulk conducting polymer film with entrapped GOx, and the nanoscale 
electrode was comprised of nanofibers with embedded GOx. Both were placed between 
microfabricated electrodes and were principally comprised of a conducting polymer, 
poly(3,4-ethylenedioxythiophene) (PEDOT), and were tested at potentials of +0.3 V and 
+0.7 V30. As a result of its larger surface area, the nanofiber sensor exhibited an improved 
signal-to-noise ratio and a higher density of GOx immobilization than the bulk film. 
Additionally, the conductivity of the nanofiber sensor was greater than the bulk film system, 
and a 433% increase in sensitivity was reported30. Further, the detection limit for the 
nanofiber sensor was 0.26 mM, compared to 0.56 mM for the bulk polymer. The nanofiber 
sensor also exhibited significantly improved sensitivity over 30 days compared to bulk 
hydrogel (83% loss of sensitivity compared to 28% loss of sensitivity).
As a result of the superior surface area and reducing ability of nanostructures, highly 
sensitive glucose sensors can be fabricated with carbon nanotubes. Tang, et al. fabricated an 
amperometric sensor using multi-walled carbon nanotubes (MWCNTs) and Platinum 
nanoparticles (Pt NPs)27. The addition of Pt NPs to platinum electrodes containing chitosan-
immobilized GOx reduced the glucose detection limit by a factor of greater than 1000 to an 
exceptionally low limit of detection of 5 nM as compared to a non-Pt NP functionalized 
sensor27. This drastic reduction in detection limit was attributed to the Pt NP’s excellent 
ability to reduce hydrogen peroxide generated by the GOx reaction 27.
To prevent contamination of the glucose signal by interfering chemical species, some groups 
have shielded their sensors from such species. This shielding is particularly important for 
sensors which utilize non-enzymatic glucose transducers, such as boronic acids. Zeng et al. 
immobilized GOx onto gold nanoparticle electrodes (AuNPs) with a chitosan hydrogel and 
covered the matrix with a thin Nafion layer to prevent interfering species from entering the 
sensor18. The sensor exhibited excellent performance as a result of the inclusion of AuNPs 
and despite the Nafion layer. The GOx-generated hydrogen peroxide was catalysed by the 
gold nanoparticle electrodes and the resulting current was measured18. The sensor was 2.8 
times more sensitive to glucose than a sensor fabricated with a flat gold electrode, and a 
linear detection range of 3.0 μm – 9.0 mM with a detection limit of 1.5 μm and a response 
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time of < 5 seconds was reported18. Additionally, Uehara, et al. developed a sponge like 
nanoporous membrane with a pore diameter of 5–30 nm16. This membrane was used to 
selectively allow the passage of glucose, while blocking larger albumin molecules16. 
Applications of this membrane could include shielding a glucose sensor from interference 
from larger molecules or preventing aggregation of large molecules on its surface. Nunes 
and co-workers developed a membrane capable of serving the same purpose, but with pH 
responsive pore diameters; pore diameters from 4–17 nm could be achieved over a pH range 
of 4.2–731.
The ability to detect both increasing and decreasing glucose concentrations, known as 
reversibility, is another important characteristic of glucose sensors and a requirement for an 
implantable continuous glucose sensor. Zhai and co-workers developed a highly reversible 
sensor with minimal hysteresis by immobilizing GOx and Platinum Nanoparticles (Pt NPs) 
within a polyaniline hydrogel matrix, and used the matrix as a conductor to measure the 
electrical activity of both the electrocatalytic action of the GOx enzymatic reaction and the 
Pt NP mediated catalysis of hydrogen peroxide32.
It is important to note that enzymes can be easily denatured, and enzymatic sensor lifetime 
may be an issue which precludes continuous in vivo glucose sensing22. Therefore, enzyme-
free modalities have been developed. Dong, et al. reported growing Cobaltosic oxide 
nanowires on grapheme foam, which are capable of direct detection of glucose (Figure 3)22. 
Ding, et al. found that the cobalt nanowires serve as a catalyst for facilitating the direct 
oxidation of glucose to gluconolactone via the following equation33:
High sensitivity (3.39 mA mM−1 cm−2) with a low detection limit (<25 nM) was reported by 
Dong, et al. in glucose concentrations from 0–1 mM22. Additionally, this reaction was found 
to be specific to glucose, as the catalysis of uric and ascorbic acid was not catalysed by the 
nanowires22. Similarly, silicon nanoparticles can be used for direct enzyme-free detection of 
glucose20, 21. Wang and coworkers were among the first to report such a system, and 
immobilized Si29 nanoparticles on a Si substrate21. The electrical activity of the catalytic 
reaction was effectively transported to the substrate, and a linear detection range from 0–50 
mM was reported. The system did not exhibit interference from ascorbic or uric acids21.
Another exciting option for glucose detection is the magnetic response technique reported 
by Sun and co-workers, who functionalized magnetic nanoparticles with Con A34. They 
found that the T2 relaxation time of the Con A functionalized nanoparticles was affected by 
the concentration of glucose due to the change in total particle mass, and reported a linear 
relationship between T2 relaxation time and glucose concentration (0–300 mg dL−1)34. The 
sensor was reported to exhibit excellent stability and is reversible, thereby making such a 
sensor a good candidate for continuous glucose monitoring. Furthermore, the toxicity of Con 
A has also been recently assessed, and has been found to be safe at low concentrations35.
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Optical glucose measurements typically involve an increase in fluorescence intensity or a 
shift in the wavelength of the light produced by a fluorescent material coupled with a 
glucose sensitive material. The implantation of reversible optical sensors has led to the 
concept of a “smart tattoo” which continuously measures BGL by modulating the tattoo’s 
optical wavelength in response to glucose concentration36. Optical sensors have a number of 
advantages, including imperviousness to electromagnetic fields, capability to be 
miniaturized for single molecule detection schemes, and the ability to be used in continuous 
real time glucose monitoring11.
Carbon nanotubes exhibit properties which make them ideal for fluorescent biosensing, such 
as emission at a near-infrared wavelengths, which is a wavelength at which skin is 
particularly transparent23. Barone, et al. was among the first to use single walled nanotubes 
(SWNTs) for fluorescent glucose sensing, and demonstrated that SWNTs functionalized 
with Fe(CN)63− exhibit a change in fluorescence when the H2O2 generated by GOx action 
reduces Fe(CN)63− on functionalized SWNTs. This sensor was found to be sensitive to 
physiologically relevant glucose concentrations (1 mM – 8 mM) and was fully reversible23. 
Inherent fluorescence of carbon nanotubes was further investigated by Yum and co-workers 
(Figure 3), who tested 30 Boronic acids with SWNTs to find combinations which yield 
accurate and reversible changes in fluorescence signals in response to glucose 
concentration29. As glucose binds to several boronic acid functionalized SWNTs, the 
fluorescence signal increased. Two Boronic acids were found which optomized the desired 
properties: 4-cyanophenylboronic and 4-chlorophenylboronic acid, and a reversible sensor 
was realized by measuring the frequency shift of the fluorescence or the “turn on” 
response29. The sensor was sensitive to physiologically relevant glucose concentrations, and 
reacted quickly to changes in glucose (~1 min)29.
Additionally, it has been demonstrated that Glucose Binding Protein (GBP) bound to 
SWNTs can be used to mechanically actuate the SWNTs upon glucose binding, and thereby 
cause a quenching of the SWNT’s fluorescence in proportion to glucose concentration28. 
Such a sensor has been demonstrated by Yoon, et al, who bound GBP to SWNTs via amine 
coupling to lysine groups on the enzyme28. The group demonstrated a 5–10% decrease in 
fluorescence intensity in the presence of 20–40 mM of glucose, and a linear response was 
found from 2.5–10 mM. The system was fully reversible and generated stable responses for 
>60 h28. McNicholas, et al. investigated the chemical changes which occur as a result of 
immobilizing GBPs on SWNTs26. They found that GBP denatures at a lower temperature 
(4–5 °C) when bound to SWNTs, and were only found to be stable below 36 °C. This 
consideration should be taken into account when preparing glucose sensors with bound 
enzymes, especially when considering in vivo implantation for long term glucose 
monitoring.
Several optical sensor approaches utilizing metal nanoparticles have been developed. First, 
He and co-workers reported developing a highly sensitive glucose sensor by immobilizing 
GOx on Ag/Au nanoshells via poly(L-histidine)6. In this case, the hydrogen peroxide 
produced by the GOx enzymatic action caused the Ag coating to dissolve and expose 
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increasingly large areas of Au on the surface of the nanoshells, thereby causing a red shift in 
surface plasmon resonance peaks6. This shift, sampled at a standard time interval, could 
detect glucose concentrations from 0.5 μM – 0.02 mM. Additionally, Bahshi and co-workers 
developed two optical techniques for detecting glucose8. The first used Glucose 
Dehydrogenase (GDH) to catalyse the production of NADH in the presence of glucose. The 
NADH caused a fluorescence increase in functionalized quantum dots (Hops Yellow Core/
Shell EviDots (CdSe/ZnS QDs), which was used to quantify glucose concentrations. 
Alternatively, the growth of Au NPs can result from the production of NADH by GDH. 
Specifically, when AuCl4− ions are present in solution, they can be reduced by the NADH 
produced by GDH action, and lead to the growth of AuNPs. This causes an increase in 
fluorescence in the visible spectral region (peaks near 530 nm) as the AuNPs grow. 
Sampling time for both systems was on the order of 20–50 min, and glucose concentrations 
tested were on the order of 0–2.5 mM8.
Nanomaterials can also be used as a catalyst to cause fluorescence of materials in the 
presence of hydrogen peroxide. This has been exploited by Song and co-workers who 
demonstrated that carboxyl modified planar graphene can catalyse the oxidation of 3,3,5,5-
tetramethylbenzidine (TMB) to produce a blue color when reacted with the hydrogen 
peroxide produced by GOx activity37. However, the catalysis of TMB by the carboxyl-
graphene requires a pH of 4, which denatures the GOx enzyme. A two-step process was 
used to overcome this, and a highly sensitive glucose detection range from 1 μm–20 μm was 
reported. Additionally, the glucose concentration of blood could be accurately measured.
Yetisen and co-workers (Figure 5) developed an optical glucose sensor by fabricating a 
poly(acrylamide) (pAAm) hydrogel functionalized with 3-(acrylamido)phenylboronic acid 
(3-PBA) and Ag NPs11. As glucose entered the hydrogel and bound to the PBA, the 
hydrophobicity of the hydrogel increased, causing it to swell in proportion to glucose 
concentration11. The swelling modulated the distance between the embedded AgNPs, and 
caused a glucose-dependent shift in the frequency of refracted laser light. After 
optimization, a possible wavelength shift of ~350 nm across the visible spectrum was 
reported for glucose concentrations ranging from 0 mM–10 mM. Additionally, achieving a 
steady state response with this hydrogel took 50 min–1.5 h, but an analysis of the transient 
response was conducted, and by applying the results of this analysis the glucose 
concentration could be accurately estimated after only 5 min11. The sensor was reported to 
be more accurate than commercially available test strips, and could detect an exceptionally 
wide range of glucose concentrations (0.1 mM–375 mM)11. This sensor was designed to 
detect the glucose concentration of urine, which correlates with BGL11.
Veetil and co-workers developed a mutant glucose binding protein (GBP) which contains 
the fluorescence resonance energy transfer (FRET) probes AcGFP1 and mCherry9. Upon 
glucose binding, the FRET pair is brought in proximity to each other, causing a change in 
the FRET signal. When the FRET pairs are separated, the intensity of 505 nm light is 
significant, but decreases sharply upon glucose binding9. The sensor could accurately detect 
glucose in the range of 25–800 μM9. Recently, this group reported expressing a similar 
mutant GBP protein within murine myoblast cells by transfecting the mutant GBP DNA into 
the cell’s DNA15. The mutant GBP protein was synthesized within the cells, and could be 
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used to analyse the glucose concentration within the cells15. The resulting ability to see real 
time glucose metabolism within the cell is important for understanding diabetes pathology 
and may be useful in understanding possible intracellular therapies15. Furthermore, this 
approach may be especially useful for studying the pathology of type 2 diabetes15. Within 
the cell, elevated glucose concentrations were found close to the cell membrane, and low 
glucose concentrations were found close to the nucleus15.
A novel method for glucose detection developed by Stuart, et al. is the adaption of Surface 
Enhanced Raman Scattering (SERS) for in vivo glucose detection by coating the surface of 
Ag NPs with decanethiol and mecaptohexanol38. This facilitates the localization of glucose 
to the NP surface and leads to a detectable FRET signal based on glucose concentration38. 
Stuart, et al. demonstrated the system in a rat model, and found that the system was capable 
of detecting glucose concentration in vivo with accuracy comparable to a commercial 
glucose sensor12, 38.
Nanotechnology Enabled Closed-Loop Insulin Delivery
An attractive alternative to traditional insulin injections are “closed-loop” systems, or 
systems which continuously monitor blood glucose and release insulin in a self-regulated 
fashion. There are several benefits of such a system over the traditional open loop system, 
including tighter control of BGLs, which can reduce the complications characteristic of 
diabtes39, 40. Closed-loop systems may also lead to a decrease in the dosage of insulin, and 
reduce the number of hypoglycemic and hyperglycemic events. These advantages have led 
to considerable interest in developing closed-loop systems. The reported systems have 
demonstrated favourable results in terms of responsiveness and biocompatibility7, 41.
Microencapsulation of Islet Cells – Artificial Pancreas
Encapsulating the body’s own insulin producing β-cells within semi-permeable polymer 
matrices, such as alginate hydrogel, is an attractive option for closed-loop insulin delivery. 
This strategy calls for the encapsulation of β-cells within a semi-permeable membrane that 
shields the cells from host immune responses while allowing small molecules, nutrients, and 
insulin to passively diffuse across the membrane. Designing such a membrane is a complex 
challenge and is being approached from several perspectives. One of the most significant 
challenges to this approach is overcoming the host’s immune response to directly implanting 
foreign islet cells. Typically, the cells are rapidly engulfed by fibrotic overgrowths as a 
result of an immune response42.
Another technique for encapsulating islet cells is the Layer by Layer (LbL) deposition of a 
semi-permeable membrane onto the cells7, 43. A persistent challenge of using LbL 
deposition for islet cell encapsulation is avoiding the use of polyionic polymers, which are 
cytotoxic44, 45. Alternative binding strategies are needed to create LbL coatings on the cells 
that have increased stability and reduced cytotoxicity. Recently, Gattas-Asfura and co-
workers reported a new LbL technique utilizing interpolymeric covalent linking to enhance 
the stability of the LbL coatings46. Alginate and poly(amidoamine) (PAMAM) dendrimers 
were functionalized with complementary Staudinger ligation groups: azide and methyl 2-
(diphenylphosphino)terephthalate. Covalent linkages and electrostatic forces between the 
DiSanto et al. Page 8













films increased the stability and thickness of the resultant bilayer. This bioorthoganal 
functionalization technique for interpolymeric linking also serves as a method for 
functionalizing the surface of the islet and can be modified to include secondary therapeutic 
agents such as immunosuppressant drugs or bioactive groups that enhance the nutrient 
supply47. However, the coatings still face the issue of cytotoxicity due to the inclusion of 
polyionic polymers.
A solution to the polyionic induced cytotoxicity was recently reported by Kozlovskaya and 
coworkers41. The group reported an LbL coating strategy that used hydrogen bonding 
between tannic acid (TA), a natural polyphenol with poly(N-vynilpyrrolidone) (PVNOP) 
which holds the polymeric films together. The interactions between TA and the cell 
membrane proteins resulted in a highly stable coating. The hydrogen bonded films 
maintained good stability for up to 7 days after the initial coating. Furthermore, the cells 
coated with the bilayers displayed no significant increase in cytotoxicity compared to un-
coated cells. Significant challenges in terms of immunoisolation of the islet cells remain 
before islet cell transplantation can become a clinically viable option.
Glucose-Responsive Insulin Delivery
Synthetic closed-loop systems are often characterized by their method of glucose detection. 
Glucose can be detected through enzymatic methods using enzymes such as glucose oxidase 
(GOx), Binding of glucose to synthetic groups such as those in Phenylboronic acid (PBA), 
or binding to glucose binding proteins such as Concavalin A (Con A)13 as seen in Figure 6.
Glucose Oxidase (GOx) Systems—Glucose oxidase is capable of enzymatically 
catalysing the oxidation of glucose to gluconic acid with high specificity. The rate of 
enzymatic production of gluconic acid is directly related to the local glucose concentration. 
A typical closed-loop system utilizing glucose oxidase is comprised of a pH sensitive 
polymer matrix containing both insulin and GOx. The matrix undergoes a physical change 
such as hydrolysis or volume phase transition as the pH of the system is altered by gluconic 
acid production, thereby releasing the insulin entrapped within the matrix in a glucose 
dependent fashion6, 13.
Gu and co-workers recently developed a glucose-responsive nano-network for insulin 
delivery using GOx as the glucose sensing element (Figure 7)48. A double emulsion method 
was used to prepare acetal modified dextran (m-dextran) nanoparticles which included 
insulin, GOx and catalase (CAT). The nanoparticles were coated with either positively 
charged chitosan or negatively charged alginate. The opposing surface charges caused the 
nanoparticles to assemble into a porous 3D nano-network. The conversion of glucose to 
gluconic acid triggered the hydrolysis of the acetal groups to ethanol and acetone which 
results in the phase transition of hydrophobic m-dextran to dextran, which is hydrophilic. 
This phase transition results in the release of the entrapped insulin in a glucose-responsive 
fashion. The nano-network architecture endowed the system with sufficient mechanical 
strength to overcome a burst release at the injection site. Furthermore, the porous structure 
led to the presence of microchannels which facilitated higher rates of glucose diffusion 
through the nano-network leading to near zero order enzyme kinetics. The system showed 
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no significant insulin release at normal glucose levels (100 mg dL−1), but transitioned to fast 
insulin release under hyperglycemic conditions (400 mg dL−1). In in vivo studies, a single 
subcutaneous injection of the nano-network was capable of maintaining a diabetic mouse’s 
blood glucose levels in the normoglycemic range for 10 days48.
More recently, Tai and co-workers developed an enzyme based biomimetic polymersome 
for glucose-responsive insulin delivery49. Polymersome nanovesicles were comprised of a 
Polyethylene glycol-poly (Ser-Ketal) PEG-Poly (Ser-Ketal) amphiphilic diblock polymer, 
GOx, CAT, and Insulin. Under neutral conditions the polymersome forms a bilayer structure 
which contains the insulin and allows glucose and oxygen to diffuse through the membrane. 
The enzymatic production of gluconic acid in response to hyperglycaemic glucose 
concentrations results in the degradation of the polymer membrane by degrading the ser-
ketal linkage into PEG-Poly(Serine), ethanol, and acetone. The degradation of the 
membrane causes a subsequent release of insulin. Alternating the nanovesicles between 
hyperglycaemic conditions (400 mg dL−1) and normoglycemic conditions (100 mg dL−1) 
resulted in a pulsatile release of insulin with maximal release at the hyperglycaemic state, 
and negligible release under normoglycemic conditions. The polymersome bilayer structure 
led to excellent mechanical stability of the system. No insulin release was observed from the 
vesicles without a glucose stimulus over a course of 1 month. In vivo studies revealed that 
insulin released from the polymersomes retained bioactivity and were effective for 
regulating the glucose levels of diabetic mice for up to 5 days.
Gordijo and co-workers developed a glucose-responsive nanocomposite membrane for 
insulin delivery10, 50. The composite was prepared by conjugating MnO2 nanoparticles and 
poly(N-isopropylacrylamide –co-methacrylic acid) poly(NIPAM-MAA) with GOx, insulin, 
catalase (CAT), bovine serum albumin (BSA) and gluteraldehyde. The resultant PNIPAM-
MAA membrane is pH sensitive and is capable of shrinking under the acidic conditions 
induced by hyperglycaemia. The shrinking of the membrane leads to insulin release across 
the membrane by increasing the porosity of the hydrogel network. However, degradation of 
the enzyme is a significant challenge for glucose-responsive systems utilizing GOx. As 
H2O2 accumulates as a product of the enzymatic reaction, the activity of GOx is degraded. 
To address this, the CAT enzyme is often included to scavenge the H2O2 and catalyse its 
conversion to O210, 48, 51. However, CAT is not capable of scavenging all the H2O2, and is 
itself affected by an increase in H2O2 concentrations. The inclusion of MnO2 NPs works 
synergistically with CAT to scavenge more H2O2. The rigid MnO2 NPs increased the 
mechanical strength of the system as well the longevity of the enclosed enzyme. Inclusion of 
the MnO2 NPs and CAT led to a nanohybrid membrane that maintained excellent activity 
for 15 days, and maintained 65% of its initial activity after 30 days.
Most glucose-responsive insulin delivery systems utilize the degradation of a polymer 
matrix or a phase transition to mediate the release of insulin. However, attention has recently 
been directed to mesoporous silica nanoparticles (MSNs) as a result of their rigid structure 
and high surface area. Recently, Chen and co-workers developed a glucose dependent drug 
release system52. The system is comprised of MSNs loaded with rhodamine as a model 
drug. The MSNs are capped with GOx bound to N-glucosamine, a GOx inhibitor, which in 
turn is bound to the outside of the NP. As the glucose concentration increases, it competes 
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with glucosamine to bind to the GOx. Glucose binding to GOx results in uncapping of the 
MSNs and leads to the release of the encapsulated drug. In vitro studies indicated that 
rhodamine release from the NP was glucose dependent, and that no release was observed in 
the absence of glucose. Furthermore, drug release was correlated with glucose 
concentration. In addition to Rhodamine, other drugs such as Insulin could be stored within 
MSNs and capped with a glucose responsive element52–54.
Glucose Binding Protein (GBP) Systems—Glucose binding proteins can bind to 
glucose or glucosyl moieties in glycopolymers5. The most common class of glucose binding 
proteins are lectins. Lectins are a family of proteins that can bind to carbohydrates, and have 
a significant role in cell signaling55. The most common lectin used for insulin delivery 
systems is Concanavalin A (Con A). It is the preferred GBP because of its high affinity for 
glucose. Con A can bind to gluconic acid modified insulin (G-insulin) and be included in 
hydrogels. Under hyperglycaemic conditions, competition between G-insulin and glucose 
leads to the release of G-insulin in a glucose dependent manner. Wu and co-workers recently 
developed a MSN system capped with Con A56. The system is comprised of Con A bound 
to a mannose moiety, which is used to cap the pores of the MSN which contain rhodamine 
as a model drug. The resulting system was both pH and glucose-responsive. Triggering of 
the system by pH occurs because Con A exists as a dimer or monomer at low pH, and 
assumes a tetrameric state at neutral pH. Competitive binding of glucose with the capped 
Con A led to a release of the drug loaded within the MSN. In the absence of a glucose or a 
pH trigger, no drug release occurred.
Phenylboronic Acid (PBA) Systems—A disadvantage of protein based glucose 
sensing is that environmental factors such as pH and temperature must be tightly controlled 
to prevent protein denaturation. The possibility of denaturation limits the glucose sensing 
applications and sensor lifetimes of protein based systems. This poses challenges for the 
long term measurement of blood glucose by such sensors. An attractive alternative is the use 
of Phenylboronic acid and its derivatives as the glucose sensing moiety in both BGL 
measurement and insulin delivery applications. The ability of Phenylboronic acid to 
reversibly bind to polyols has been well established57. This has allowed Boronic acid 
derivatives to serve as the detection element in glucose-responsive insulin delivery and BGL 
measurement applications.
Phenylboronic acid in its neutral form exists as a trigonal planar hydrophobic molecule but 
is deprotonated under slightly basic conditions (pKa> 8) where it exists as a tetrahedral 
hydrophilic molecule with a net negative charge. The equilibrium between the two states is 
pushed towards the tetrahedral state in the presence of diols and polyols such as those found 
in glucose 58. This equilibrium can be utilized to trigger the dissolution of amphiphilic 
nanocarriers and thus release insulin59–63. The equilibrium shift from the neutral to the 
charged form can also trigger the swelling of crosslinked hydrogel matrices.
Kataoka et al. were the first to report a synthetic glucose-responsive system for insulin 
delivery in 199858. The group synthesized a polymer matrix of poly (N-
isopropylacrylamide) (PINPAAm) that included PBA as a glucose sensing moiety. Upon 
glucose complexation with the PBA, the hydrophilicity of the matrix increased, causing the 
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matrix to swell and release insulin in a glucose-responsive fashion64. Since this initial work 
several other insulin delivery systems have been devised which utilize the PBA moiety for 
its glucose sensing properties48, 60, 65, 66.
One approach for glucose-responsive insulin delivery is the use of crosslinked polymer 
matrices with incorporated PBA. These matrices can reversibly swell when PBA forms a 
boronate ester with glucose. The ester formation leads to an accumulation of negative charge 
on the matrix, which results in repulsive forces that cause the cross-linked matrix to swell 
and release insulin. Recently, Wang and co-workers developed a co-polymer micelle 
comprised of poly (ethylene glycol)-block-poly-(acrylic acid-co-acryloamidophenylboronic 
acid) - (PEG-b-(PAA-co-PAAPBA)59. The micelle was capable of swelling in response to 
glucose concentration. The core of the micelle shifted from being hydrophobic to 
hydrophilic as the glucose formed a complex with the PBA moiety in the core of the micelle. 
The insulin stored within the micelle was then released in glucose dependent manner. In the 
absence of glucose the micelle was stable and no insulin release was detected.
One of the primary issues with using PBA in clinical systems is that the tetrahedral form 
requires a pH higher than those observed in most physiological systems. Yao and co-
workers developed a polymeric glucose-responsive insulin delivery system that operates 
under neutral pH conditions60. Their system is comprised of an amphiphilic polymer made 
of Poly(ethylene glycol)-block-poly[(2-phenylboronic esters-1,3-dioxane-5-ethyl) 
methacrylate] (MPEG5000-block-PBDEMA). Electron donating groups were included 
within the polymer to increase its Lewis acidity and thereby reduce the pKa required to form 
the boronate ester. This co-polymer self assembles into micelles, and the system releases 
insulin upon the matrix’s transition from amphiphilic to hydrophilic.
Yang et al. devised a similar system utilizing a PBA sensing scheme at physiological pH 
using micelles67. The micelles were prepared by synthesizing a block co-polymer containing 
poly(ethylene glycol)-b-poly(aspartic acid co-aspartamidophenylboronic acid) PEG-b-
P(Asp-coAspPBA) along with a poly(Aspartic acid co aspartglucosamine)-P(Asp-co-AGA) 
glycopolymer. The introduction of glycopolymers into the polymer structure of the micelle 
allowed it to remain relatively stable under normoglycemic conditions (1 g L−1) due to the 
competition between the glycopolymer and glucose binding to PBA. However, at elevated 
glucose concentrations (2 g L−1), the micelles disintegrated and rapidly released insulin. The 
system was stable at normal blood sugar levels, and this stability reduced the risk of a burst 
release of insulin, which is highly desirable in a self-regulating insulin delivery device.
Polymer based insulin delivery systems have great versatility. Modifying the structure of the 
polymer can be used to tune the insulin release behaviour and sensitivity. Kim and co-
workers synthesized a PEG-polyboroxole block co-polymer polymersome which was 
capable of self-assembly into micelles or cylindrical polymersomes based on the 
polyboroxole block length68. The group reported that at neutral pH, binding of the boroxole 
group to monosaccharides such as glucose (0.5 M) and fructose (0.2 M) was capable of 
producing charged boronate groups in the core of the polymersome. This change in charge 
modified the core’s behavior from hydrophobic to hydrophilic, thereby causing the 
polymersome to dissociate and release embedded cargos such as insulin. The polymersomes 
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did not dissolve in the absence of monosaccharaides, and instead maintained their 
morphology for up to 3 months. The boroxole group showed a stronger binding affinity for 
fructose over glucose, but the versatility this system shows promise for self-regulated insulin 
delivery platforms.
Several groups have attempted to create platforms which exhibit a step wise response to 
glucose concentration and can deliver multiple drugs. Zhao and co-workers used 
Mesoporous Silica Nanoparticles (MSNs) as a platform for glucose-responsive release of 
Insulin and cyclic adenosine monophosphate (cAMP) – a trigger for the production of 
insulin from pancreatic beta cells69. The MSNs were loaded with cyclic AMP and capped 
with PBA bound to gluconic acid modified insulin (G-insulin). The system used the 
preferential binding of glucose to PBA to release the G-insulin-PBA cap from the MSNs, 
thereby liberating both insulin (in the G-insulin form) and cAMP. Furthermore, MSNs have 
been shown to be internalized by cells through endocytosis; this facilitates the uptake of 
cAMP, which normally encounters difficulty in crossing the cell membrane. The system was 
well realized and showed almost no leaching of cAMP without a glucose or fructose trigger. 
20 mM glucose was capable of releasing 2 μM of G-insulin at a MSN concentration of 2 mg 
mL−1. An ideal payload of insulin to lower blood glucose is about 200–350 pM 69. 
Furthermore, the release of cAMP was also glucose-responsive at a glucose concentration of 
100 mM; 60% of the loaded cAMP was released from the MSN. 0.25 to 0.3 μM of MSN 
was capable of delivering a therapeutic dose of insulin in a glucose-responsive manner. The 
prospect of a dual delivery system is an exciting one, and has led to an increase in interest in 
MSNs for insulin delivery37, 52, 66, 70. However, the modification of insulin with gluconic 
acid raises questions about the bioavailability of the drug once released from the MSN.
Wu and coworkers designed a multifunctional hybrid nanogel system to serve as an insulin 
delivery device and glucose sensor (Figure 8)10, 62. The nanogel is comprised of poly(4-
vynilphenylboronicacid-co-2-(diethylamino)ethyl acrylate) p[VPBA-DMAEA] polymer 
chains which serve as the glucose sensing moiety. The polymer is capable of crosslinking to 
form a nanogel which undergoes a phase transition in response to glucose concentration. 
The group included silver nanoparticles in the core of the nanogel that endows it with strong 
fluorescence. The wavelength of this flourescence changes as the nanogel swells and shrinks 
in proportion to glucose concentration. In addition to the sensing mechanism, the system is 
also capable of dispensing insulin in a glucose-responsive fashion by swelling in response to 
hyperglycaemic conditions. The system was capable of phase transitions at a physiologically 
relevant pH (7.4) and exhibited high sensitivity to glucose; a lower detection limit of 0.75 
mM was reported. The nanogels could release 56–91% of the stored insulin at high glucose 
levels, and could quickly modulate between high and low insulin release rates in response to 
changing glucose concentrations. Insulin release at basal levels could be sustained for over 2 
days.
Conclusion and Outlook
Significant advances in both glucose sensors and self-regulated insulin delivery systems 
have been facilitated by nanotechnology. Amperometric sensors utilizing nanotechnology 
now facilitate rapid, accurate, and highly sensitive glucose measurements in blood and other 
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clinically relevant fluids, such as tears and urine. Additionally, recent advances in 
fluorescent glucose detection holds the potential to lead to continuous in vivo glucose 
measurement. The realization of sensors which do not require repeated finger pricks to draw 
blood for glucose testing is highly desirable, as alternatives which avoid the pain, tissue 
damage, and patient noncompliance associated with the legacy clinical standard are highly 
desirable5. Furthermore, the clinical realization of a continuous glucose sensor could lead to 
closed-loop systems which could utilize existing insulin pumps6. This could relieve the 
patient of the significant burden of continuously managing their diabetes, and may 
tremendously improve their long term health outcomes and well-being. Based on current 
developments in nanoscale glucose sensing, we can expect great clinical applications of this 
technology in the near future71.
Progress in closed-loop insulin delivery systems has been encouraging and shows 
tremendous promise for the treatment of diabetes. Recently, a Con-A based polymer 
approach developed by Zion, et al has been close to clinical trials, following his company’s 
2010 acquisition by Merck72, 73. Current closed-loop systems are capable of releasing large 
amounts of insulin; however, clinical realization requires tight control of insulin release to 
reduce the risk of insulin overdose. Glucagon, a hormone which works antagonistically with 
insulin, could be co-delivered to reduce the risk of hypoglycaemia3. Additionally, because 
insulin is a growth factor, long term exposure to excess insulin can cause changes to the cell 
division process74.
Systems that offer remote control for the release of insulin are a promising development in 
dynamic insulin delivery. Stanley and co-workers developed nanoparticles coated with 
antibodies capable of binding to TRPV1 calcium channels on genetically engineered cells. 
The application of a 465 kHz RF signal causes localized heating of the channel via heating 
of the nanoparticles, and this heating causes subsequent passage of calcium into the cell, 
triggering the production of insulin within the cell75. The cells then release this insulin into 
the bloodstream75. Additionally, Di, et al. demonstrated insulin release via the bursting of 
nanocapsules by focused ultrasound (FUS)76. A nano-network48 comprised of PLGA 
nanoparticles containing insulin was used to form an insulin reservoir, which could be 
selectively degraded by the application of focused ultrasound and lead to insulin release in 
response to ultrasound application76. These remotely triggered strategies may lead to novel 
insulin delivery modalities which can reduce the pain associated with repeatedly injecting 
insulin and increase patient compliance,5 and may serve as an element of closed-loop 
glucose therapies. The best way of tackling the challenges ahead is by taking a 
multidisciplinary approach and incorporating knowledge of material science, physical 
chemistry, and pharmacology to develop more nuanced systems that are dynamic and stable.
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Schematic of research themes using nanotechnology for diabetes treatment.
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Yang, et al investigated how nanowires can affect the sensitivity of amperometric glucose 
sensors. In this experiment, two types of sensors were developed; the first was formed by 
immobilizing GOx within a bulk hydrogel, and the second was formed by immobilizing 
GOx on the surface of conductive nanowires. This figure depicts a schematic of the two 
types of glucose concentration sensors: (a–c) A bulk hydrogel glucose sensor with 
embedded GOx. (a,d–g) A nanowire glucose sensor with embedded GOx. (h,i) The glucose 
sensor apparatus. (j–k) The bulk hyrdogel-GOx sensing system. (i–m) The nanowire-GOx 
based glucose sensing system. The nanowire based sensor was more sensitive than the bulk 
film sensor, which was attributes to its larger surface area, increased GOx loading capacity, 
and lower electrical resistance. (Reprinted with permission from Ref 30. Copyright 2014 
John Wiley & Sons)
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The cobalt nanowires in this image can directly oxidize glucose without the use of enzymes, 
and thereby generate an amperometric signal proportional to the glucose concentration. An 
extremely small detection limit was reported (<25nM), and was attributed to the extremely 
large surface area of the sensor. This figure depicts scanning electron microscopy images of 
(A) Graphene foam; (B) Cobalt nanowires grown on the surface of graphene foam; (C) 
Graphene Foam functionalized with cobalt nanowires; (D) High magnification of cobalt 
nanowires; (E) Image of a single cobalt nanowire. (Reprinted with permission from Ref 22. 
Copyright 2012 American Chemical Society)
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In this study, Yum, et al used fluorescent carbon nanotubes with boronic acid to fabricate an 
optical glucose sensor. As the boronic acid binds to the nanotubes, the fluorescence is 
quenched. As glucose binds to these boronic acids, the fluorescence returns. Two Boronic 
acids were found which optomized the desired properties: 4-cyanophenylboronic and 4-
chlorophenylboronic acid. (Reprinted with permission from Ref 29. Copyright 2011 
American Chemical Society)
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In this study, a boronic acid functionalized hydrogel was formed and included suspended 
silver nanoparticles. The functionalized hydrogel swelled and contracted in proportion to 
glucose concentration, as a result of the binding interaction between glucose and the boronic 
acid. As the hydrogel swells, the distance between the Au NPs modulates in response to 
glucose concentration, and thereby causes a shift in the wavelength of the refracted light. A 
wavelength shift of 350nm across the visible spectrum was reported for glucose 
concentrations ranging from 0mM–10mM. (Reprinted with permission from Ref 11. 
Copyright 2014 American Chemical Society)
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Schematic of typical strategies for glucose responsive insulin release. (Reprinted with 
permission from Ref 5. Copyright 2014 Chemical Society Reviews)
DiSanto et al. Page 24














Schematic of the glucose-responsive nano-network. (A) Acetal modified dextran 
nanoparticles containing insulin and GOx. The nanoparticles are coated with positively 
charged chitosan or negatively charged alginate. (B) Acetal modified dextran molecule. (C) 
Assembly of oppositely charged nanoparticles to form a nano-network and insulin release 
upon the enzymatic generation of gluconic acid under hyperglycaemic conditions. (D) 
Injection of the nano-network into a STZ-induced diabetic mouse model. (Reprinted with 
permission from Ref 48. Copyright 2013 American Chemical Society)
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Glucose-responsive insulin delivery systems utilizing phenylboronic acid. (A) Insulin 
release via pH responsive micelles. (B) Multifunctional hydrogel for glucose-responsive 
insulin release and glucose concentration measurement. As the smart hydrogel swells in 
response to hyperglycemic conditions, the insulin is released and the fluorescence of the 
silver nanoparticles (AgNPs) is modulated. This fluorescence change can be detected and 
used to quantify the glucose concentration and the release of insulin. (Reprinted with 
permission from Ref 62. Copyright 2012 American Chemical Society)
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Table 1
Summary of reported glucose measurement systems.
Type Detection Principle Response Time Detection Limit Reference Number
Optical Nanotube Near-IR emission ~1 min 34.7 μM 23
Nanotube Fluorescence Enhancement ~ 1min 2.5 mM 28
Fluorescence Enhancement and AuNP Growth 30–60 min 0.01 mM (QDs); 0.1 mM (AuNPs) 8
Graphene Catalytic Activity 1h 1 μM 37
Nanotube Fluorescence Enhancement ~1 min 5 mM 29
Raman spectroscopy ~10 min 0.5 μM 6
Hydrogel Mediated Bragg Diffraction 5 min 90 μM 11
Protein FRET signal ~1 min 25 μM 9
Electrical
Nanotube conductance modulation ~20 s 0.1 mM 24
Hydrogen Peroxide catalysis via Nanotubes <20 s 0.08 mM 25
Hydrogen Peroxide catalysis <5 s 1.5 μM 18
Hydrogen Peroxide catalysis via AuNPs <30 s 180 μM 17
Nanomaterial enhanced conductance modulation <20 s 0.5 μM; 5 μM 27
Nanomaterial enhanced conductance modulation <20 s 0.56 mM; 0.26 mM 30
Enzyme-free glucose catalysis <20 s <25 nm 22
Nanoparticle catalysis of Hydrogen Peroxide 3 s 0.7 μM 32
Enzyme-free glucose catalysis <20 s 1 mM 21
Magnetic Shift in magnetic resonance of a membrane <1 min -- 34
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